SWISS MEDICAL NETWORK



Dr. med. Jesica Mazza-Stalder

Spécialiste en Pneumologie, membre FMH

Sprachen

EN,FR,ES

Berufserfahrung

seit 2022	Vice president of Vaud Lung League
seit 2013	Medical Officer of Public Health for tuberculosis VD (Tuberculosis 10%)
seit 2013	Medical Advisor in Respiratory Medicine at the Vaud Lung League (10%)
seit 2011	Senior consultant at the Division of Respiratory Medicine (30%) University Hospital of Lausanne Switzerland (CHUV) and private practice in Pulmonary Medicine at Nyon (60% of activity)
2008–2011	Chief of Residents, Respiratory Division CHUV
2007–2008	Chief of Residents (Chef de Clinique) Thoracic Surgery Division CHUV
2005–2007	Respiratory Medicine as MD at University Hospital of Geneva
2004–2005	Respiratory Medicine training as a resident (MD) at Rolle Hospital
2001–2004	Respiratory Medicine Residency (resident) at CHUV
1996–1999	Chief of Residents and residency of Internal Medicine Central Military Hospital

Ausbildung

2009	Federal Swiss Diploma
2007	Doctorate Unil University of Lausanne Switzerland
2007	FMH Respiratory Medicine
1999	Internal Medicine Specialist (Buenos Aires- Argentina)
1989–1995	Medical Doctor education Faculty of Medicine Buenos Aires University (UBA)

Kompetenzen

A la suite de ses études de médecine achevées en 1995 à l'Université de Buenos Aires en Argentine (UBA), Jesica Mazza-Stalder se spécialise en médecine interne et commence sa formation de pneumologie à la Fundacion Favaloro à Buenos Aires. Arrivée en Suisse en 2001, elle poursuit sa formation au CHUV, premièrement comme interne de pneumologie au CHUV, ensuite à l'Hôpital de Rolle, puis aux HUG.

En 2007, de retour au CHUV, elle devient chef de clinique dans le Service de chirurgie thoracique, puis dans le service de Pneumologie jusqu'en avril 2011 où elle est nommée médecin agréé.

Les axes de recherche de Jesica Mazza-Stalder concernent la mucoviscidose, la transplantation pulmonaire et la tuberculose. Dans le cadre de son activité au sein du service de pneumologie et en particulier au dispensaire antituberculeux (DAT), des liens ont été établis entre la Ligue pulmonaire vaudoise et la santé publique.

Publikationen

2020 Tadolini, GB Miggliori et al Eur Respir J may 2020
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases

2019 Borisov S, et al....Mazza-Stalder J, Nicod LP, Miggliori GB Eur Respir J 2019 Dec 19,54 (6) Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

2019 J Mazza-Stalder, E Chevallier, O Opota, A Carreira, K Jaton, E Masserey, J P Zellweger, L P Nicod. Frontiers in Medicine. Published June 2019. Improvement in tuberculosis outcomes with a combined medical and social approach

2019 Opota O, Mazza-Stalder J, Greub G, Jaton K. The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection. Clinic Microbiol Infection 2019 Nov doi: 10.1016/j.cmi.2019.03.021. Epub 2019 Mar 28

2019 Zakham F1, Laurent S1, Esteves Carreira AL2, Corbaz A2, Bertelli C1, Masserey E3, Nicod L2, Greub G1, Jaton K1, Mazza-Stalder J2, Opota O1. New Microbes New Infect. 2019 Jun 29; 31:100582. doi: 0.1016/j.nmni.2019.100582. eCollection 2019 Sep. Whole-genome sequencing for rapid, reliable and routine investigation of Mycobacterium tuberculosis transmission in local communities

2019 Simon A, Opota O, Mazza-Stalder J, Nicod L, Greub G, Nicod L, Jaton K. Added diagnostic value of 16S rRNA gene pan mycobacterial for nontuberculous mycobacterial infections: a 10 year retrospective study

2018 O Opota, F Zakham, J Mazza-Stalder, L Nicod, G Greub, K Jaton. Added Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a Low Prevalence Setting. J Clin Microbiol 2018 57:e01717-18

2018 Walker TM, Merker M, Knoblauch AM, Helbling P, Schoch OD, van der Werf MJ, and the MDR-TB Cluster Consortium. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. Lancet Infect Dis. 2018;18(4):431-40

2016 Opota O, Senn L, Prod'hom G, Mazza Stalder J, Tissot F, Greub G, Jaton K. Added value of molecular assay Xpert MTB/RIF compared to sputum smear microscopy to assess the risk of tuberculosis transmission in a low-prevalence country. Clin Microbiol Infect. 2016 Jul;22(7):613-9. doi: 10.1016/j.cmi.2016.04.010. Epub 2016 Apr 29

2016 Stucki D, Ballif M, Egger M, Furrer H, Altpeter E, Battegay M, Droz S, Bruderer T, Coscolla M, Borrell S, Zürcher K, Janssens JP, Calmy A, Mazza Stalder J, Jaton K, Rieder HL, Pfyffer GE, Siegrist HH, Hoffmann M, Fehr J, Dolina M, Frei R, Schrenzel J, Böttger EC, Gagneux S, Fenner L. Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country.J Clin Microbiol. 2016 Jul;54(7):1862-70. doi: 10.1128/JCM.00126-16.

2015	Rozot V, Amelio P, Vigano S, Mazza-Stalder J, Idrizi E, Day Cheryl, Perreau M, Lazor-Blanchet C, Ohmiti K, Goletti D, Bart P. A, Hanekom W, Scriba Th, Nicod L, Pantaleo G and Harari A. Clinical infectious disease 2015. Combined Use of M Tuberculosis-specific CD4 and CD8 T cell is a Powerful Diagnostic tool of Active Tuberculosis
2013	Bridevaux P-O, Aubert J-D, Soccal P M, Mazza-Stalder J, Berutto C, Rochat T, Turin L, Van Belle, Nicod L. P et al Thorax september 2013 Incidence and Outcomes of respiratory viral infections in lung transplant recipients: a prospective study
2013	Perreau M, Rozot V, Welles HC, Belluti-Enders F, Vigano S, Maillard M, Dorta G, Mazza-Stalder J, Bart PA, Roger T, Calandra T, Nicod L, Harari A. Eur J Immunol. 2013 Apr; 43(4):939-48. Lack of Mycobacterium tuberculosis-specific interleukin-17A-producing CD4+T cells in active disease
2013	Rozot V, Mazza-Stalder J, Nicod L. P, Harari A. et al EJI 2013. Mycobacterium tuberculosis-specific CD8+ T Cells are functionally and phenotypically different between latent infection and active disease
2012	Mazza-Stalder J, Nicod L., Janssens JP. Revue des Maladies respiratoires April 2012. Extra-pulmonary tuberculosis
2011	Harari A, R Rozot V, Bellutti Enders F, Perreau M, Mazza-Stalder J, Nicod L., Cavassini M, Calandra Th, Lazor Blanchet K, Jaton K, Faouzi M, Day Ch, Willem A. Hanekom, Bart P-A and Pantaleo G. Nature Med 2011. Dominant TNF-a Mycobacterium Tuberculosis-Specific CD4 T-Cell Responses Discriminate Between Latent Infection and Active Disease
2010	Uçkay I, Gasche-Soccal PM, Kaiser L, Stern R, Mazza-Stalder J, Aubert JD, van Delden C. J Heart Lung Transplant. 2010 Mar; 29(3):299-305. Epub 2009 Oct 17. Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy
2010	Boillat Blanco N, Kuonen R, Bellini C, Manuel O, Estrade C, Mazza-Stalder J, Aubert JD, Sahli R, Meylan P. Transpl Infect Dis. 2010 Aug 30. Chronic norovirus gastroenteritis in a double hematopoietic stem cell and lung transplant recipient
2009	Mazza-Stalder J, Lador F, Soccal-Gasche P, Aubert J. Evaluation of pulmonary arterial pressure in lung transplant candidates: transthoracic echocardiographie versus right heart catheterization. "Best poster at the Swiss Society of Pulmonary Hypertension. ERS Vienna 2009/ and 4th International Congress of the Swiss Society for Pulmonary Hypertension. SSPH Zurich 2009: Best Poster
2009	Mazza-Stalder J, Janton-Ogay K, Nicod L. Revue medicale Suisse nov 2009. Non tuberculous mycobacteria pulmonary disease: what's new?
2008	Mazza-Stalder J, Sistek, J. P. Revelly, S. D. Qanadli, A. Sauty. Massive haemoptysis in cystic fibrosis adult patients. ERS 2008. P1244. 5.10.2008
2005	Mazza-Stalder J, Siegrist CA, Janssens JP. Rev Med Suisse. 2005 Nov 16; 1(41):2645-6, 2649-51. Immunization and immuno-modulation for prevention of respiratory tract infections
2003	Mazza-Stalder J, Sauty A. 48h-continuous interstitial glucose monitoring in non-diabetic cystic fibrosis patients: a pilot study. Journal of Cystic Fibrosis 2 (suppl1), pp. S79, 2003
2003	Mazza-Stalder J, Sauty A. Le syndrome hépatopulmonaire (SHP). Médecine et Hygiène 2458, 12 Nov 2003
2002	Mazza-Stalder J, Sauty A. Significance of macrophage predominance in pleural effusions. Oral presentation ERS congress Schweiz Med Forum suppl 7, pp 20S 2002

Mitgliedschaften

Member of the Board Swiss TB

Vice President of Lung League Vaud

seit 2011	International Union against Tuberculosis and Lung disease
seit 2007	Swiss Respiratory Society

seit 1999 European Respiratory Society

Akkreditierung

Clinique de Genolier

Fachgebiete

Pneumologie

Kontakt

Clinique de Genolier
Route du Muids 3
1272 Genolier

T +41 22 994 28 03
jmazza-stalder@genolier.net
https://www.genolier.net

vCard herunterladen